Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00760396 · ClinicalTrials.gov registry record · Phase 1
Multiple-Dose Study of VGX-1027 in Healthy Subjects
A Phase 1 study, sponsored by VGX Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 40
- Enrollment target
NCT00760396: Completed Phase 1 study, sponsored by VGX Pharmaceuticals.
NCT00760396 is a Phase 1 study that has completed, run by VGX Pharmaceuticals. The registered enrollment target is 40 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00760396, a Phase 1 study, has completed, sponsored by VGX Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 40 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety profile, tolerability and pharmacokinetics following multiple oral doses of 40mg to 200mg VGX 1027 in healthy subjects administered for 5 days.
Interventions
- DRUG VGX-1027
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2008-09 |
| Est. Completion | 2009-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00760396
The ClinicalTrials.gov registry entry for NCT00760396 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is VGX Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which VGX-1027 is the first listed.
NCT00760396 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00760396 about?
NCT00760396 is a clinical study titled "Multiple-Dose Study of VGX-1027 in Healthy Subjects". The purpose of this study is to evaluate the safety profile, tolerability and pharmacokinetics following multiple oral doses of 40mg to 200mg VGX 1027 in healthy subjects administered for 5 days.
What is the current status of trial NCT00760396?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 40 participants. The study started on 2008-09. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00760396?
The interventions under investigation include: VGX-1027 (DRUG).
Who is sponsoring clinical trial NCT00760396?
This trial is sponsored by VGX Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.